Abbot's Brain Stimulation System Approved to Treat Parkinson's
Abbott Laboratories (NYSE: ABT) announced on Friday that it's Infinity Deep Brain Stimulation (DPS) system had received approval from the Food and Drug Administration (FDA) to target specific areas of the brain associated with motor functions. More specifically, the expanded indication permits Abbott's DPS system to target the internal globus pallidus (GPi), a specific part of the brain that regulates voluntary movement.
This specific part of the brain, when stimulated, has been associated with helping improve motor-function related Parkinson's symptoms. DPS therapy can also help Parkinson's patients who are dealing with side-effects from medications, such as involuntary muscle movements and spasms (also known as dyskinesia).
Image source: Getty Images.
Source Fool.com
